Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.34 – $1.65
3% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | −$4.7M | $0 | $0 | $289.0K |
| Cost of revenue | $0 | $76.0K | $203.0K | $218.0K | $361.0K | $406.0K | $488.0K | $561.0K |
| Gross profit | $0 | −$76.0K | −$203.0K | −$218.0K | −$5.0M | −$406.0K | −$488.0K | −$272.0K |
| Gross margin | — | — | — | — | 107.7% | — | — | -94.1% |
| R&D | $26.4K | $887.0K | $3.9M | $3.9M | $8.1M | $7.0M | $6.3K | $7.2M |
| Operating income | −$39.6K | −$1.3M | −$6.3M | −$12.2M | $14.9M | −$12.1M | $11.3K | −$13.6M |
| EBITDA | $0 | −$4.5M | −$7.0M | −$16.7M | −$14.7M | −$10.9M | −$11.1K | −$13.2M |
| Net income | −$39.6K | −$4.6M | −$7.2M | −$17.0M | −$4.0M | −$11.3M | −$11.1K | −$13.2M |
| Net margin | — | — | — | — | 85.5% | — | — | -4574.4% |
| EPS (diluted) | -0.02 | -0.34 | -1.01 | -3.20 | -1.39 | -0.93 | -0.00 | -0.45 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $48M | $0.10 | $0.10–$0.10 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds IINN.
No tracked institution reports a position in IINN as of their last filing.
No one on the platform has traded IINN yet.
| $20M |
| — |
| LSTALisata Therapeutics, Inc. | $3.36 | -0.59% | $31M | — |
| MTVAMetaVia Inc. | $1.43 | -6.54% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.